NME2 and fibrodysplasia ossificans progressiva: However, it is challenging to use an AAV-based CRISPR/ABE system as an in vivo gene therapy for FOP due to several limitations, such as immune reactions against the bacterial nuclease Nme2-ABE, off-target cleavage and mutagenesis, and the induction of chromosomal aberrations.